This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Balanitis and Balanoposthitis – Basics Terminology [Assim 2022, Dynamedex 2024, Perkins 2024] Balanitis – Inflammation of the glans penis Posthitis – Inflammation of the foreskin (prepuce) Balanoposthitis – Inflammation of both (ouch!)
Accessed May 7, 2022. Accessed May 7, 2022. Accessed May 7, 2022. Accessed May 7, 2022. StatPearls Publishing; 2022. Accessed May 17, 2022. Table 1: Comparison of F(ab) and F(ab’) 2 antivenoms. References: Ubani C, DeGelorm A, Sollee D. Poison Control: The F(ab2)ulous Expanded Indication of Anavip | FCEP.
American Gastroenterological Association issued a practice guideline in November 2022 recommending that semaglutide 2.4 Retrospective study published in 2022 of 81,752 adverse events associated with GLP-1 agonist therapy found an increased risk of pancreatitis, particularly with liraglutide (ROR 32.67; 95% CI 29.44-36.25).
What They Did: Parallel, 2-arm, noninferiority, open-label, multicenter, international randomized clinical trial Occurred in 6 specialized centers (3 in North America – US & Canada and 3 Outside of North America – Australia) Trial took place from June 2021 to December 2022 Used PEN-FAST to risk stratify patients.
An understanding of the risks involved including allergicreaction, radiation exposure, contrast extravasation, and contrast-associated nephropathy allows for a thorough risk-benefit analysis prior to ordering these studies. American Journal of Roentgenology 2022, 218 (3), 544-551. Emerg Radiol 2022, 29 (2), 291-298.
Philadelphia, PA: Elsevier; 2022:1-11. 101,33 (2022): e30116. Updated 2022 Nov 14]. Answer : Leukopenia Overview Leukopenia is defined as total WBC count < 4000/mm 3 Neutropenia is the most common subset of leukopenia and is defined on absolute neutrophil count: 1 Mild (1.01.5 10^9/L) Moderate (0.50.9 Medications: 25.6%
. “111 years of allergen-immunotherapy: a long and successful history of the only available disease-modifier in allergic diseases.” ” Allergologie select 6 (2022): 248. FDA approves first medication to help reduce allergicreactions to multiple foods after accidental exposure. Feb 16, 2024.
Sometimes it seems like the world is out to get us: bees in our garden, pollen in the air, nuts in our brownies, any number of other things that could trigger an allergicreaction ranging from itchy eyes and a runny nose all the way to anaphylaxis. In the first episode of our two-parter on allergies, we explore that very question.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content